Makubi Abel, Lwakatare Johnson, Ogah Okechukwu S, Rydén Lars, Lund Lars H, Makani Julie
School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden; Muhimbili National Hospital, Dar es Salaam, Tanzania. Email:
School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; Muhimbili National Hospital, Dar es Salaam, Tanzania.
Cardiovasc J Afr. 2017 Sep/Oct;28(5):331-337. doi: 10.5830/CVJA-2017-001.
Anaemia and iron deficiency (ID) are common and of prognostic importance in heart failure (HF). In both conditions the epidemiology, diagnosis and therapies have been extensively studied in high-income countries but are still largely unexplored in sub-Saharan Africa (SSA). The lack of adequate and robust epidemiological data in SSA makes it difficult to recognise the significance of anaemia and ID in HF. From a clinical perspective, less attention is paid by clinicians to screening for anaemia in HF, and as far as interventions are concerned, there are no clinical trials in SSA that provide guidance on the appropriate interventional approach. Therefore studies are needed to provide more insight into the burden and peculiarities of and intervention for anaemia and ID in HF in SSA, where the pathophysiology might be different from that in high-income countries. There is increasing appreciation that targeting ID may serve as a useful additional treatment strategy for patients with chronic HF in high-income countries. However, there is limited information on the diagnosis of and therapy for ID in HF in SSA, where infections and malnutrition are more likely to influence the situation. This article reviews the present epidemiological gap in knowledge about anaemia and ID in HF, as well as the diagnostic and therapeutic challenges in SSA.
贫血和缺铁在心力衰竭(HF)中很常见且具有预后重要性。在这两种情况下,高收入国家对其流行病学、诊断和治疗都进行了广泛研究,但在撒哈拉以南非洲(SSA)仍基本未被探索。SSA缺乏充分且可靠的流行病学数据,这使得难以认识到贫血和缺铁在HF中的重要性。从临床角度来看,临床医生对HF患者贫血筛查的关注较少,就干预措施而言,SSA没有临床试验能为合适的干预方法提供指导。因此,需要开展研究,以更深入了解SSA中HF患者贫血和缺铁的负担、特点及干预措施,因为其病理生理学可能与高收入国家不同。人们越来越认识到,针对缺铁可能是高收入国家慢性HF患者一种有用的额外治疗策略。然而,关于SSA中HF患者缺铁的诊断和治疗信息有限,在那里感染和营养不良更可能影响病情。本文综述了目前关于HF患者贫血和缺铁的流行病学知识差距,以及SSA中的诊断和治疗挑战。